Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL)

Tipranks - Tipranks - Sat Feb 7, 11:14AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (ILMN – Research Report) and Ocular Therapeutix (OCUL – Research Report).

Claim 50% Off TipRanks Premium

Illumina (ILMN)

Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Illumina today. The company’s shares closed last Friday at $120.69.

According to TipRanks.com, Ryskin is a 4-star analyst with an average return of 4.4% and a 56.2% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Currently, the analyst consensus on Illumina is a Hold with an average price target of $135.63, representing a 7.7% upside. In a report released today, Barclays also maintained a Sell rating on the stock with a $110.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Ocular Therapeutix (OCUL)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix today and set a price target of $21.00. The company’s shares closed last Friday at $9.06.

According to TipRanks.com, Chen is a 3-star analyst with an average return of 2.8% and a 44.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Virax Biolabs Group Ltd. Class A, and Orchestra BioMed Holdings. ;'>

Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $23.86, representing a 162.8% upside. In a report issued on January 28, Piper Sandler also maintained a Buy rating on the stock with a $31.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).